CAMBRIDGE, Mass. — Axoft has raised $55 million in an oversubscribed Series A round to accelerate global clinical trials and pursue U.S. regulatory approval for its implantable brain-computer interface technology.
The funding round was led by C.P. Group Innovation, with participation from Alumni Ventures, the Stanford President’s Venture Fund, Hillhouse Investment and Gaorong Ventures. The company has now raised more than $60 million in total funding.
Axoft said it will use the capital to expand clinical trials worldwide, advance regulatory pathways in the United States, and build a good manufacturing practice facility to scale production of its implantable brain-computer interfaces, known as iBCIs.
The company’s devices are designed to decode brain signals and could improve diagnosis and communication for patients with disorders of consciousness. Neurological conditions remain the leading cause of disability globally, affecting roughly one in three people.
Axoft’s platform is built on its proprietary Fleuron material, a bio-inspired polymer engineered to more closely match the softness of brain tissue. The company says the material is up to 10,000 times softer than traditional polyimide used in existing implants, helping reduce tissue scarring and device movement while improving long-term signal stability.
The softer material also allows for greater access to brain regions and higher-density data collection, enabling more detailed neural recordings over time. That data could support the development of artificial intelligence tools for identifying disease biomarkers and tailoring treatments.
“At Axoft, the neural data quality we unlock doesn’t just make iBCIs more effective, it opens the door to minimally invasive surgery, allows access to deeper brain regions and enables the next generation of AI-driven real-time decoding. Better neural signals are the foundation everything else is built on,” said Paul Le Floch, co-founder and CEO of Axoft.
The company said it has already implanted its devices in 11 patients across early clinical studies. Research published in Nature has demonstrated the platform’s ability to capture high-resolution neural activity at the single-cell level.
Recent milestones include collaborations with Mass General Brigham for cortical mapping and seizure monitoring, as well as a clinical study with The Panama Clinic involving patients undergoing brain tumor surgery. The company also launched commercial access to its Fleuron material through a licensing agreement with Stanford University and entered a joint development partnership with Kayaku Advanced Materials.
Axoft has received additional support from the Massachusetts Manufacturing Innovation Initiative to help build out its manufacturing capabilities.
The company recently opened a subsidiary in Grenoble, France, and plans to expand its engineering, microfabrication and chemistry teams while building a cleanroom facility in the Boston area.
